Pharma ADMET Testing Global Market Opportunities and Strategies to 2035

This report describes and explains the pharma ADMET testing market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global pharma ADMET testing market reached a value of nearly $10.69 billion in 2025, having grown at a compound annual growth rate (CAGR) of 12% since 2020. The market is expected to grow from $10.69 billion in 2025 to $18.06 billion in 2030 at a rate of 11%. The market is then expected to grow at a CAGR of 10.4% from 2030 and reach $29.62 billion in 2035.

Growth in the historic period resulted from rising pharma-related R&D spending, growth in rare disease and orphan drug programs, expansion of combination therapy development and expansion of precision medicine and targeted therapies. Factors that negatively affected growth in the historic period were rising cost of in vivo animal studies and ethical restrictions and stringent regulatory requirements.

Going forward, expansion of high-throughput screening (HTS) platforms, growth in multi-omics integration, rising public scrutiny of drug safety, shift toward complex biologics and novel modalities will drive growth. Factors that could hinder the growth of the pharma ADMET testing market in the future include limited high cost of preclinical testing and toxicology requirements, long duration of ADMET studies delays development timelines and impact of trade war and tariff.

The pharma ADMET testing market is segmented by testing type into in vivo ADMET testing, in vitro ADMET testing and in silico ADMET testing. The in vitro ADMET testing market was the largest segment of the pharma ADMET testing market segmented by testing type, accounting for 47.7% or $5.1 billion of the total in 2025. Going forward, the in vitro ADMET testing segment is expected to be the fastest growing segment in the pharma ADMET testing market segmented by testing type, at a CAGR of 13.1% during 2025-2030.

The pharma ADMET testing market is segmented technology into cell culture, high throughput, molecular imaging and OMICS technology. The cell culture market was the largest segment of the pharma ADMET testing market segmented by technology, accounting for 37% or $3.96 billion of the total in 2025. Going forward, the high throughput segment is expected to be the fastest growing segment in the pharma ADMET testing market segmented by technology, at a CAGR of 13.6% during 2025-2030.

The pharma ADMET testing market is segmented application into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity and other applications. The systemic toxicity market was the largest segment of the pharma ADMET testing market segmented by application, accounting for 37% or $3.7 billion of the total in 2025. Going forward, the renal toxicity segment is expected to be the fastest growing segment in the pharma ADMET testing market segmented by application, at a CAGR of 14.5 % during 2025-2030.

North America was the largest region in the pharma ADMET testing market, accounting for 34.3% or $3.66 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the pharma ADMET testing market will be Asia Pacific and Eastern Europe where growth will be at CAGRs of 13.8% and 11% respectively. These will be followed by Africa and Middle East where the markets are expected to grow at CAGRs of 9.8% and 9.1% respectively.

The global pharma ADMET testing market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 11.92% of the total market in 2024. Thermo Fisher Scientific Inc. (PPD ICON plc) was the largest competitor with a 1.31% share of the market, followed by IQVIA Inc. with 1.29%, Charles River Laboratories International Inc. with 1.28%, Laboratory Corporation of America Holdings (Covance Inc.), with 1.25%, Eurofins Scientific SE, with 1.24%, Wuxi AppTec Co. Ltd. with 1.23%, Agilent Technologies Inc. with 1.17%, Perkinelmer Inc. with 1.10%, Evotec A.G. (Aptuit LLC, Cyprotex Limited) with 1.04% and Catalent Inc. with 1.01%.

The top opportunities in the pharma ADMET testing market segmented by testing type will arise in the in vitro ADMET testing segment, which will gain $4.33 billion of global annual sales by 2030. The top opportunities in the pharma ADMET testing market segmented by technology will arise in the high throughput segment, which will gain $3.14 billion of global annual sales by 2030. The top opportunities in the pharma ADMET testing market segmented by application will arise in the systemic toxicity segment, which will gain $2.62 billion of global annual sales by 2030. The pharma ADMET testing market size will gain the most in the USA at $1.94 billion.

Market-trend-based strategies for the pharma ADMET testing market include establishment of dedicated peptide laboratories to support pharma ADMET testing, expansion of DMPK infrastructure to strengthen large-scale ADMET testing capabilities, adoption of digital platforms to streamline DMPK and ADMET testing workflows, launch of online ordering platforms to improve access to ADMET testing services and adoption of automated analytical workflows to improve medicinal chemistry and ADMET testing efficiency.

Player-adopted strategies in the pharma ADMET testing market include focus on strengthening its business through strategic partnerships and expanding its operational capabilities through new launches.

To take advantage of the opportunities, the analyst recommends the pharma ADMET companies to focus on predictive and integrated admet testing capabilities, focus on expansion of dmpk infrastructure for scalable testing capacity, focus on digital platforms for workflow efficiency and data integration, focus on digital access and automated workflows for service delivery, focus on adoption of automated analytical workflows to enhance efficiency, focus on in vitro admet testing to capture higher growth and efficiency gains, focus on high throughput testing to capture rapid market expansion, focus on renal toxicity testing to capture fastest growing segment, expand in emerging markets, continue to focus on developed markets, focus on expanding global and digital distribution channels, focus on integrated global and digital distribution networks, focus on data-driven scientific promotion and targeted outreach, focus on strategic partnerships and industry engagement for brand positioning, focus on building specialized scientific talent and client-centric expertise.

This product will be delivered within 3-5 business days.